Background-Very low levels of cardiac troponin T are associated with an increased risk of cardiovascular death in patients with stable chronic coronary disease. Whether high-sensitivity cardiac troponin T levels are associated with adverse cardiovascular outcomes in individuals without cardiovascular disease (CVD) has not been well studied. Methods and Results-Using 2 complementary study designs, we evaluated the relationship between baseline cardiac troponin and incident CVD events among diabetic and nondiabetic participants in the Women's Health Study (median follow-up, 12.3 years). All diabetic women with blood specimens were included in a cohort study (nϭ512 diabetic women, nϭ65 events), and nondiabetic women were sampled for inclusion in a case-cohort analysis (nϭ564 comprising the subcohort, nϭ479 events). High-sensitivity cardiac troponin T was detectable (Ն0.003 g/L) in 45.5% of diabetic women and 30.3% of nondiabetic women (PϽ0.0001). In models adjusted for traditional risk factors and hemoglobin A 1c , detectable high-sensitivity cardiac troponin T was associated with subsequent CVD (myocardial infarction, stroke, cardiovascular death) in diabetic women (adjusted hazard ratio, 1.79; 95% confidence interval, 1.04 to 3.07, Pϭ0.036) but not nondiabetic women (adjusted hazard ratio, 1.13; 95% confidence interval, 0.82 to 1.55; Pϭ0.46). Further adjustment for amino-terminal pro-B-type natriuretic peptide and estimated renal function did not substantially alter this relationship among diabetic women (hazard ratio, 1.76; 95% confidence interval, 1.00 to 3.08; Pϭ0.0499), which appeared to be driven by a 3-fold increase in CVD death that was not observed in nondiabetic women. Conclusions-Very low but detectable levels of cardiac troponin T are associated with total CVD and CVD death in women with diabetes mellitus. Among healthy nondiabetic women, detectable compared with undetectable troponin was not associated with CVD events. (Circulation. 2011;123:2811-2818.)
T he presence of circulating cardiac troponin (TnT) when measured with conventional TnT assays is a strong predictor of adverse outcome in patients with acute coronary syndromes, heart failure, and chronic coronary disease. [1] [2] [3] [4] [5] [6] [7] [8] However, these conventional assays are of limited use in healthier patients without preexisting heart disease, because most healthy patients do not have detectable levels of TnT with these standard assays. 9
Clinical Perspective on p 2818
Recently, newer assays for circulating TnT with nearly 10 times the detection limit of conventional assays have become available. Compared with the conventional assays, newer assays improve the speed and accuracy of the diagnosis of acute coronary syndromes. 10, 11 In high-risk patients with established coronary disease or heart failure, TnT levels that are below the limit of detection of conventional assays and within the normal range of the newer assays predict adverse cardiovascular outcomes, including cardiovascular death. 12, 13 Recently published results from the Cardiovascular Health Study and the Dallas Heart Study extend those observations to a primary prevention population of elderly men and women and to a general population, including subjects with prior overt or subclinical heart disease. 14, 15 However, data in lower-risk populations such as middle-aged women are lacking, and many of the published studies of patients with chest pain, heart failure, or coronary disease have included few women. 12, 13, 16 Finally, data are scarce among patients with diabetes mellitus, a condition known to be associated with elevated baseline conventional TnT levels. 9 To further evaluate these issues, we measured TnT levels using a novel high-sensitivity assay in baseline blood samples among 2 groups of women: diabetic and nondiabetic participants in the Women's Health Study (WHS). Women were followed prospectively for incident myocardial infarction, stroke, and cardiovascular death. We hypothesized that circulating TnT levels would be higher among diabetic than nondiabetic subjects, and that TnT levels that were detectable but in the normal range would be associated with future cardiovascular events in both groups of women.
Methods

Study Participants and End-Point Ascertainment
Study participants were enrolled in the WHS, a completed randomized, double-blind, placebo-controlled 2ϫ2 factorial trial of aspirin and vitamin E in the prevention of cardiovascular disease (CVD) and cancer among 39 876 female health professionals Ն45 years of age. Enrollment began in 1992, and a total of 28 345 women provided a blood sample at baseline. Among these, 19 871 (70.1%) were fasting at the time of sample collection. The randomized portion of the study was completed in March 2004, and women were invited to participate in continued observational follow-up. Subjects have been followed up continuously for incident CVD, a composite of nonfatal myocardial infarction, nonfatal ischemic stroke, or cardiovascular death. The methods of end-point validation have been described elsewhere in detail. 17
Laboratory Analysis
Plasma high-sensitivity TnT (hsTnT) was measured with an electrochemiluminescent immunoassay assay provided by Roche Diagnostics (Indianapolis, IN). According to the manufacturer, the lower limit of detection of the high-sensitivity assay is 0.003 g/L. The lower limit of detection with the conventional Roche assay is 0.01 g/L. The value at the 99th percentile in a population of healthy blood donors is 0.0135 g/L, and the 10% coefficient of variation concentration has been reported to be less than this value. 18 Recent work has defined an abnormal level of hsTnT to be Ն0.014 g/L, so we have adopted that convention for this study. 19 
Study Subjects
All subjects were selected from among women with adequate fasting baseline blood specimens. Two complementary study designs were implemented on the basis of baseline diabetes status.
Diabetic Women
All women who reported a diagnosis of diabetes mellitus on the enrollment questionnaire and had blood samples available for analysis were included in the diabetes cohort (nϭ512).
Nondiabetic Women
We designed a case-cohort study of nondiabetic women by first selecting a random sample of CVD cases (nϭ464) from among the entire WHS cohort. A randomly selected subcohort of nondiabetic women (nϭ564) was then chosen as a reference risk set. Selection of this reference subcohort of nondiabetic women was independent of CVD case status. Fifteen participants who were randomly selected for the reference subcohort of nondiabetic women developed incident CVD, increasing the total number of CVD events included in the case-cohort analysis to 479. The selection of the reference subcohort was stratified by race/ethnicity (white versus nonwhite) and age (in 5-year strata) to approximately match the distribution among CVD cases. This nondiabetic reference subcohort, which comprised a total of 564 women, was used for the analysis of the distribution of hsTnT levels and associated covariates.
Statistical Analysis
High-Sensitivity Cardiac Troponin T Levels and Associated Covariates in Diabetic and Nondiabetic Women
Baseline clinical covariates and the distribution of hsTnT in diabetic women (nϭ512) and the reference subcohort of nondiabetic women (nϭ564) were compared by use of the 2 and Wilcoxon rank-sum tests for categorical and continuous variables, respectively. Nondiabetic women selected solely on the basis of CVD case status (nϭ464) were not included in this analysis. We defined a priori 3 ways to compare hsTnT levels in diabetic women with those in the reference subcohort of nondiabetic women: as a continuous variable, as the proportion of women with detectable hsTnT levels (Ն0.003 g/L), and as the proportion of women with abnormal hsTnT levels (Ն0.014 g/L). 19 We assessed clinical and biochemical correlates of baseline detectable (Ն0.003 g/L) compared with undetectable (Ͻ0.003 g/L) TnT by calculating odds ratios, 95% confidence intervals (CIs), and P values separately for diabetic and nondiabetic women from the reference subcohort. ␤ Coefficients for each univariable correlate of detectable hsTnT in diabetic women were compared with those in nondiabetic women by use of a 2-sided Z test. Two independent multivariable-adjusted regression models for diabetic and nondiabetic women were constructed with the use of backwards selection, with an inclusion threshold for the final model of PϽ0. 15 . Candidate variables included those analyzed in the previous univariable logistic regression analysis. When current smoking was selected for multivariable models, past smoking was forced into the model so that the referent group remained never smokers. During the model selection process, to prevent the addition of 2 variables that were likely to be collinear, we included systolic blood pressure rather than a history of hypertension and total cholesterol rather than lowdensity lipoprotein cholesterol or history of elevated cholesterol. Models including history of hypertension in place of systolic blood pressure or low-density lipoprotein cholesterol or history of elevated cholesterol in place of total cholesterol yielded similar results (data not shown). As a secondary analysis, independent stepwise logistic regression procedures in diabetic and nondiabetic women were used to confirm that no important associations between baseline clinical covariates and a detectable hsTnT were missed. The significance thresholds for covariable entry and retention were set at PϽ0.15.
High-Sensitivity Cardiac Troponin T and Incident Cardiovascular Disease in Diabetic and Nondiabetic Women
Cox proportional hazards models were used to calculate adjusted hazard ratios (HRs) and 95% CIs for incident CVD (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) according to the presence of detectable TnT (Ն0.003 g/L). The risk of incident CVD associated with a detectable TnT was calculated separately for diabetic women (analyzed as a cohort) and nondiabetic women (analyzed as a case-cohort). Similar Cox proportional hazards modeling techniques were used in diabetic and nondiabetic women, except that adjustments were made in nondiabetic women to account for the weighted sampling technique and the case-cohort study design. 20 Evidence for statistically significant differences in ␤ coefficients for the association between a detectable TnT (Ն0.003 g/L) and incident CVD in the diabetic compared with the nondiabetic women was assessed with a 2-sided Z test. Women without complete information for all covariables included in multivariable models were excluded from those analyses. A maximum of 40 of the 512 diabetic women (7.8%) and 32 of the 1028 nondiabetic women (3.1%) were excluded for missing covariate information. The proportional hazards assumption was examined in diabetic and nondiabetic women by including a time by detectable hsTnT interaction term in the model. No violation of this assumption was detected. All analyses were performed with SAS 9.1 for UNIX.
Results
Baseline Characteristics and Distribution of High-Sensitivity Cardiac Troponin T
Baseline characteristics of the diabetic women and the nondiabetic women from the reference subcohort are displayed in Table 1 .
Women with diabetes mellitus were similar in age to nondiabetic women, but were more likely to have a history of high cholesterol and elevated blood pressure. Diabetic women had higher median body mass index, high-sensitivity C-reactive protein, estimated glomerular filtration rate, and hemoglobin A 1c (HbA 1c ) levels and lower high-density lipoprotein cholesterol levels.
The hsTnT levels in diabetic women were higher than among nondiabetic women (PϽ0.0001). Although 30.3% of nondiabetic women had detectable levels of hsTnT, this proportion was much higher among diabetic women (45.5%; PϽ0.0001; Table 2 ). Only 2% of healthy nondiabetic women included in the cohort had elevated (Ն0.014 g/L) hsTnT levels. Among diabetic women, that proportion was nearly twice as high (3.9%), although the difference was not statistically significant (Pϭ0.055).
The distribution of detectable hsTnT levels in diabetic and nondiabetic women is displayed in the Figure. Among those with a detectable hsTnT, the median hsTnT was higher in diabetic women (0.0060 g/L; interquartile range, 0.0044 to 0.0084) than in nondiabetic women (0.0049 g/L; interquartile range, 0.0039, 0.0071; Pϭ0.0002). Only 2 of 512 diabetic women (0.4%) and 2 of 564 nondiabetic women (0.4%) had 
Figure.
Distribution of detectable high-sensitivity cardiac troponin T levels (Ն0.003 g/L) in diabetic women and in the reference subcohort of nondiabetic women.
TnT levels that would have been detectable with previousgeneration assays (hsTnT Ն0.030 g/L).
Baseline Characteristics Associated With a Detectable High-Sensitivity Cardiac Troponin T
The univariable associations of clinical and biochemical covariates with a detectable hsTnT level among diabetic women and the nondiabetic reference subcohort are displayed in Table 3 . The strength and direction of association for most correlates were similar in women with and without diabetes mellitus. However, increasing levels of total and low-density lipoprotein cholesterol were associated with increased odds of a detectable hsTnT in diabetic women and decreased odds of detectable hsTnT in nondiabetic women, a difference that was statistically significant (Table 3 ). Although HbA 1c was correlated with hsTnT in diabetic and nondiabetic women, the relationship was significantly stronger in nondiabetic women. Variables retained in the multivariable models are shown in Table 4 . Similar results were observed for all covariates when a stepwise regression procedure was used, when low-density lipoprotein cholesterol was included in models instead of total cholesterol, and when history of hypertension was used instead of systolic blood pressure.
High-Sensitivity Cardiac Troponin T and Incident Cardiovascular Events
Among diabetic women, a detectable level of hsTnT at baseline was associated with nearly double the risk of the composite cardiovascular end point (HR, 1.95; 95% CI, 1.17 to 3.23; Pϭ0.01) after adjustment for age and race ( Table 5 ). This risk estimate was modestly attenuated, but remained statistically significant after the addition of traditional cardiovascular risk factors and high-sensitivity C-reactive protein (model 2 in Table 5 ) and the addition of HbA 1c (model 3 in Table 5 ). After adjustment for the complete set of covariables, including amino-terminal pro-B-type natriuretic peptide and estimated glomerular filtration rate, we observed a 76% increase in risk of the composite CVD end point (HR, 1.76; 95% CI, 1.00 to 3.08; Pϭ0.0499; model 4 in Table 5 ).
In contrast, among nondiabetic women, a detectable hsTnT was not associated with incident CVD ( Table 5 ). As shown, the calculated HRs ranged from 1.07 (95% CI, 0.81 to 1.40) in models adjusted for age and race to 1.15 (95% CI, 0.82 to 1.59) in models adjusted for traditional cardiovascular risk factors, high-sensitivity C-reactive protein, HbA 1c , aminoterminal pro-B-type natriuretic peptide, and estimated glomerular filtration rate (Table 5 ). This difference in association between hsTnT and CVD in diabetic compared with nondi- abetic women was statistically significant in the age-and race-adjusted model 1 (Pϭ0.04) but not after further adjustment (P for models 2 through 4 ranged from 0.12 to 0.20). The association between a detectable hsTnT and incident CVD among women with diabetes mellitus appeared to be driven by a Ͼ3-fold increase in the risk of cardiovascular death in age-and race-adjusted models (HR, 3.25; 95% CI, 1.17 to 9.01; Pϭ0.02; Table 6 ). This risk was only modestly attenuated after adjustment for the full set of covariables (HR, 3.13; 95% CI, 0.99 to 9.95; Pϭ0.053). Apart from this finding in women with diabetes mellitus, a detectable hsTnT was not associated with an increased risk of myocardial infarction, stroke, or coronary revascularization in either group of women (Table 6 ). Excluding women with elevated levels of TnT (hsTnT Ն0.014 g/L) did not substantially alter these results. In diabetic women, the addition of hsTnT to fully adjusted models for either the composite cardiovascular end point or cardiovascular death significantly improved model fit (Pϭ0.046 and 0.037, respectively). The association between detectable TnT levels and incident CVD in women with diabetes mellitus was not modified by HbA 1c levels above or below the median of 7% (P for interactionϭ0.10) or by a history of hypertension, a history of high cholesterol, age Ն60 years, or body mass index Ն30 kg/m 2 (each P for interaction Ͼ0.40). The lack of association between a detectable hsTnT and incident CVD among nondiabetic women was also consistent across these subgroups.
Because prior studies in secondary prevention, 13 elderly, 14 and general 15 populations have reported an increased risk of CVD even among those with normal hsTnT levels (Ͻ0.014 g/L), we conducted a secondary analysis in the nondiabetic women to determine whether slightly higher hsTnT levels were associated with increased CVD risk. We identified nondiabetic women with hsTnT levels greater than or equal to the median detectable hsTnT level in the reference subcohort (0.00521 g/L). Compared with women with undetectable hsTnT levels, these women were at modestly, nonsignificantly increased risk of all CVD (HR, 1.33; 95% CI, 0.86 to 2.06; Pϭ0.30) and CVD death (HR, 1.46; 95% CI, 0.76 to 2.81; Pϭ0.34).
Discussion
In these prospective analyses, we report that nearly half of women with diabetes mellitus and a third of women without diabetes mellitus had levels of TnT that were detectable with a new-generation TnT assay, and that all but four of those women had TnT levels that were below the limit of detection of the previous generation of assays. Furthermore, in women Table 4 with diabetes mellitus, these very low but detectable TnT levels were associated with a Ͼ3-fold increase in the adjusted risk of cardiovascular death, even though the vast majority of women had TnT levels within the range considered normal. In contrast, among women without diabetes mellitus, these very low but detectable levels of TnT were not significantly associated with the composite cardiovascular end point or any of its components, including cardiovascular death.
. Multivariable-Adjusted Association Between Baseline Characteristics of Diabetic and Nondiabetic Women and a Detectable High-Sensitivity Cardiac Troponin T (>0.003 g/L) at Baseline in the Women's Health Study
We believe that these data are of clinical importance for several reasons. First, very low levels of TnT were detectable in a significant minority of the women without diabetes mellitus (30%) and a larger proportion of women with diabetes mellitus (45%). The prevalence of an elevated hsTnT (Ն0.014 g/L) in the reference subcohort of nondiabetic women was 2%, a number consistent with data from other studies of healthy men and women. 13, 15, 18 These data suggest that, although the prevalence of an elevated hsTnT in our nondiabetic cohort is similar to that in other healthy populations, there is evidence of chronic, ongoing release of small amounts of myocardial TnT into the circulation in both diabetic and nondiabetic women. Not surprisingly, the prevalence of a detectable TnT in both of these groups of women, who do not have clinically evident CVD, is lower than what has been observed in higher-risk populations, such as those with prevalent coronary disease, heart failure, or advanced age. 13, 14, 21 Our observation that increasing age, blood pressure, HbA 1c , and amino-terminal pro-B-type natriuretic peptide are associated with increased odds of a detectable hsTnT is consistent with prior data, 9, 13, 15, 16 and the lack of association between other risk markers, such as low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and body mass index is consistent with some, 7, 9, 12, 16 but not other, 13 published reports. Recent findings from the Dallas Heart Study support an independent association between detectable hsTnT and cardiac structural abnormalities that relate to heart failure risk such as increased left ventricular mass, wall thickness, or chamber size. In contrast, markers of myocardial infarction risk such as angina, prior myocardial infarction, or coronary artery calcium were not independent predictors of detectable hsTnT. 15 Other studies have also reported correlations between structural heart disease and detectable levels of hsTnT. 14 -16 Although we were unable to assess these associations in our study, we did observe a strong univariable correlation between the metabolic marker HbA 1c and detectable hsTnT, even among nondiabetic women. These results raise the possibility that alterations in glucose metabolism that precede the onset of clinical diabetes mellitus may be an important mechanism of myocardial cell injury.
Second, these very low but detectable levels of TnT were associated with a significantly increased risk of incident CVD in women with but not in women without diabetes mellitus. The increased risk of the combined cardiovascular end point in women with diabetes mellitus appeared to be due largely to an increased risk of cardiovascular death rather than nonfatal myocardial infarction or stroke. These data are consistent with 2 prior studies of the novel assay conducted in higherrisk patients, including those with established but stable coronary disease and the elderly men and women enrolled in the Cardiovascular Health Study. 13, 14 Both studies observed an increased risk of cardiovascular death even for subjects with hsTnT levels that were well below the limit of detection of conventional assays and within the normal range of the novel assay used in this study. Although the pathobiological mechanisms leading to this increased risk of cardiovascular ‡Multivariable adjusted hazard ratios are adjusted for covariables included in model 4 from Table 5 , including age, race, body mass index, history of hypertension, current smoking, parental history of myocardial infarction, total cholesterol, high-density lipoprotein cholesterol, natural logarithm of high-sensitivity C-reactive protein, hemoglobin A 1c , and the natural logarithms of amino-terminal pro-B-type natriuretic peptide and estimated glomerular filtration rate. Women without complete information for all covariables included in the multivariable model were excluded from the analysis. death among those with a detectable hsTnT have yet to be clearly defined, they are likely to be related to myocardial structural abnormalities that have previously been reported to be associated with circulating TnT. 14 -16 There are a number of possible explanations for our findings in nondiabetic women. First, although the prevalence of detectable TnT in otherwise healthy women was high, it was lower than in other populations of more advanced age. Thus, some level of circulating TnT may be normal, at least in women without diabetes mellitus who are at low absolute CVD risk. 13, 14 We did note a subtle, nonsignificant increase in CVD risk with slightly higher levels of hsTnT in the nondiabetic women. This finding is consistent with previously published observations in other populations, and suggests that a value closer to the 99th percentile in healthy populations might be a better threshold to use to determine cardiovascular risk among healthy, nondiabetic subjects. 18 However, recently published results from the Dallas Heart Study suggest an elevated risk of both all-cause and cardiovascular mortality across a range of hsTnT levels that are still within what is defined as normal (Ͻ0.014 g/L). This risk was consistent across sex, diabetes status, and the presence of preexisting CVD. 15 One possible explanation for the different results in our study is that the predominantly white female health professionals enrolled in the WHS had better access to routine preventive medical care, which may have attenuated mortality risk associated with an elevated hsTnT.
Alternatively, detectable TnT in women without diabetes mellitus may reflect a normal biological process of myocyte turnover that at very low levels is not associated with increased risk of adverse cardiovascular outcome, whereas the observation of relatively higher prevalence of detectable TnT in women with diabetes mellitus may reflect a more malignant process of accelerated cell turnover caused by subclinical epicardial coronary disease, chronic microvascular ischemia, or cardiomyopathy with attendant risk of adverse cardiovascular outcomes. One mechanism specific to the diabetic heart is a shift to fatty acid metabolism, which may lead to increased oxidative stress, which has previously been shown in animal models to precipitate TnT release. 22, 23 In multivariable models, blood pressure and aminoterminal pro-B-type natriuretic peptide, both measures of cardiac wall stress, were associated with detectable hsTnT among diabetic women but not among nondiabetic women. This observation raises the possibility that the diabetic myocardium may be more vulnerable to the deleterious effects of elevated blood pressure. Alternatively, the observed discrepancy between women with and without diabetes mellitus in this study may be due to the absence of congestive heart failure in our CVD definition. This end point has been associated with detectable TnT levels in patients with chronic heart failure, 12 chronic stable coronary disease, 13 and the elderly. 14 Thus, if nondiabetic women with detectable hsTnT were more likely to develop heart failure than to die of cardiovascular causes, those events would not have been captured by our study design.
Finally, the fact that our data suggest that very low but detectable levels of TnT provide independent prognostic information for women with diabetes mellitus, even after controlling for traditional and novel cardiovascular risk markers, raises the possibility that hsTnT could serve as a complementary marker of cardiovascular risk and a means of further risk stratification in patients with diabetes mellitus. This possibility is intriguing because the rates of macrovascular complications of diabetes mellitus remain high, even with treatment strategies designed for aggressive control of glucose, 24 -26 blood pressure, 27 and lipids. 28
Strengths and Limitations
Our study has a number of strengths and limitations that merit consideration. Our study was performed in middle-aged women, who have been underrepresented in previous studies of new hsTnT assays, 12, 13, 16 and who were healthy at the time of enrollment and blood sampling. Our prospective study design included a large number of incident cardiovascular events, including many cardiovascular deaths. Baseline diabetes mellitus was assessed by self-report; thus, the possibility of misclassification exists. However, WHS participants were all female health professionals, among whom self-report of various chronic health conditions has proven accurate in prior validation studies. 29 Nonetheless, misclassification by diabetes status would tend to bias our results toward the null. Although our sample may not be representative of the overall US population, the prevalence of an elevated TnT in our cohort is consistent with that observed in other healthy populations (ie, Ϸ1% to 2%). Thus, we were unable to assess whether an elevated hsTnT level (Ն0.014 g/L), instead of a detectable hsTnT level (Ն0.003 g/L), is a marker of future cardiovascular risk. Finally, validated heart failure events were not available, limiting our ability to evaluate the reported association between a detectable hsTnT and incident heart failure in a healthy population.
Conclusions
Very low but detectable levels of TnT are common, and are associated with incident CVD, particularly cardiovascular death, in women with diabetes mellitus. Among initially healthy women without diabetes mellitus, detectable compared with undetectable TnT was not associated with incident cardiovascular events, including cardiovascular death.
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